Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market

Executive Summary

With its $1.9 billion bid for personal-care and over-the-counter drug manufacturer Chattem, French pharmaceutical giant Sanofi-Aventis stands to gain a toehold in the sizeable U.S. consumer health sector and beef up its presence in emerging markets
Advertisement

Related Content

Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap
Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares
Prospect Of L’Oreal Share Buyback Excites Investors
Nepentes Buy Continues Sanofi's Consumer Product Shopping Spree
Nepentes Buy Continues Sanofi's Consumer Product Shopping Spree
Chattem absorbs costs as Sanofi deal nears close
Chattem absorbs costs as Sanofi deal nears close
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
Advertisement
UsernamePublicRestriction

Register

RS016647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel